AOD-9604: Research, Benefits & Safety

Quick facts

Class: GH fragment (176–191) analog
Studied for: Fat loss / obesity
Key finding: Phase 2 trials did not beat placebo for weight loss
Approval: Not FDA-approved as a drug
Drug class: hGH fragment (176-191) peptide
Development stage: Failed obesity clinical trials
Approval status: Not approved
Common status: Marketed as research chemical / unapproved

Key takeaways

AOD-9604 is a synthetic fragment of human growth hormone corresponding to amino acids 176-191, originally investigated for fat loss.
Despite marketing claims, it failed to show meaningful weight loss versus placebo in clinical obesity trials.
It is not approved as a drug for obesity or any other indication by the FDA.
It is widely sold as a research chemical or supplement ingredient, a use that is not supported by approval or robust efficacy data.
Its proposed mechanism of stimulating fat breakdown without affecting growth hormone pathways was not borne out by clinical results.

Overview

AOD-9604 is a synthetic peptide derived from a fragment of human growth hormone, corresponding to the region spanning amino acids 176 to 191. It was developed in an effort to isolate the fat-metabolizing properties of growth hormone while avoiding the broader metabolic effects associated with the full hormone, and it has been heavily marketed as a fat-loss compound.

Despite this marketing, AOD-9604 is not an approved medication for obesity or weight loss anywhere it has been studied for that purpose. Clinical development as an anti-obesity drug did not succeed, and the peptide did not demonstrate the weight-reduction benefits that its early framing promised.

Today AOD-9604 circulates largely through compounding pharmacies, wellness clinics, and online vendors, often accompanied by claims that outpace the available evidence. An honest assessment places it as an investigational fragment with a disappointing clinical record, not a validated therapy, and consumers should treat promotional claims with skepticism.

How it works

AOD-9604 represents the carboxyl-terminal fragment of growth hormone, the portion historically associated with the hormone's lipolytic, or fat-breakdown, activity. The original rationale was that this fragment could stimulate the breakdown of stored fat and inhibit fat formation without raising IGF-1 or affecting blood glucose the way full growth hormone can.

In laboratory and animal studies, the fragment was reported to influence fat metabolism through effects on adipose tissue, potentially mimicking some of growth hormone's actions on lipid handling without engaging the growth-promoting pathway. This selective profile was the core of its theoretical appeal.

However, mechanisms that appear promising in cell cultures or animal models frequently fail to translate into meaningful effects in humans. The proposed mechanism for AOD-9604 remains incompletely validated in people, and the gap between its theoretical activity and its actual clinical performance is a central caution surrounding the compound.

Research & evidence

AOD-9604 underwent clinical evaluation as a candidate obesity treatment. The pivotal human trials did not show statistically meaningful weight loss compared with placebo, and development as an anti-obesity pharmaceutical was not carried forward to approval. This failure is the most important fact about the compound and is frequently omitted from marketing.

Some later interest shifted toward other potential applications, including exploratory work on cartilage or joint-related effects, but such investigations are limited and do not establish the peptide as an effective treatment for any condition. The body of high-quality human evidence remains thin.

In summary, the research record does not support AOD-9604 as an effective fat-loss agent in humans. Claims of dramatic body-composition changes are not backed by the published trial outcomes, and the peptide should be understood as an investigational substance whose primary clinical test did not succeed.

Safety & legal status

Because AOD-9604 has not completed the rigorous approval process for any indication, its long-term safety profile in humans is not well characterized. Short-term studies suggested it was generally tolerated, but the absence of large, long-duration trials means meaningful safety questions remain unresolved.

Product sold outside regulated channels carries additional risks. Peptides obtained from research-chemical vendors or unverified compounders may differ in purity, dosing, and sterility, introducing hazards unrelated to the molecule itself. This guide does not provide administration protocols.

Legally, AOD-9604 is not an FDA-approved drug, and its status as a dietary ingredient or compounded product is contested in various jurisdictions. In competitive sport, growth-hormone-related fragments fall under anti-doping scrutiny, and athletes should not assume the substance is permitted. Anyone considering it should recognize that they would be using an unapproved compound with limited evidence.

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide corresponding to a fragment (amino acids 176-191) of human growth hormone. It was developed and studied as a potential anti-obesity agent.

Does AOD-9604 cause fat loss?

Clinical trials did not demonstrate significant weight loss compared with placebo, and its development as an obesity drug was discontinued. Marketing claims of fat loss are not supported by approved clinical evidence.

Is AOD-9604 approved or legal as a drug?

It is not approved as a drug for any indication. It is often sold as a research chemical or supplement ingredient, but such use is unapproved and not backed by demonstrated efficacy.

How was AOD-9604 supposed to work?

It was hypothesized to mimic the fat-reducing portion of growth hormone, stimulating lipolysis without the broader effects on blood sugar or growth. Clinical results, however, did not confirm meaningful benefit.

Is AOD-9604 safe?

Because it lacks approval and large-scale safety evaluation for ongoing use, its long-term safety is not well established. Products sold online are unregulated and may vary in content and purity.

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

Related guides: Semaglutide · Tirzepatide · Tesamorelin · All Weight Loss & Metabolic peptides →

AOD-9604